Clioquinol has been shown to have anticancer activity in several carcinoma cells. In this study, we preliminarily examined the effect of clioquinol in human SMMC-7721 hepatoma and QSG-7701 normal hepatic cells. Our results indicated that clioquinol did not significantly affect survival of QSG-7701 cells, whereas it reduced cell viability in a concentration-and time-dependent manner in SMMC-7721 cells. Clioquinol did not trigger autophagy and apoptosis, while it induced cell cycle arrest in the S-phase in SMMC-7721 cells. Additionally, down-regulation of cyclin D1, A2, E1, Cdk2 and up-regulation of p21, p27 were detected after the treatment with clioquinol. The results demonstrated for the first time that clioquinol suppressed cell cycle progression in the S-phase in SMMC-7721 cells via the p21, p27-cyclin E,A/Cdk2 pathway. This suggests that clioquinol may have a therapeutic potential as an anticancer drug for certain malignances.
Clioquinol (5-chloro-7-iodoquinolin-8-ol), a quinoline compound, acts as a mild metal chelator and/or ionophore, binding metals like copper and zinc. It has been used as an antibacterial drug for treating diarrhea and skin infections (1) . However, clioquinol was withdrawn from the market due to subacute myelo-optic neuropathy (SMON) in Japan (2, 3) . In recent years, toxicology studies of clioquinol performed in both animals and humans show it has low side effects (4, 5) . Owing to its ability to bind copper/zinc and dissolve beta-amyloid plaques by activating autophagy in the brain, clioquinol has re-emerged as a potential therapy for Alzheimer's disease (6, 7) . Clioquinol was also reported to have anticancer activity in several carcinoma cells (8) (9) (10) (11) . Especially, in preclinical models of hematologic malignancies and solid tumors, clioquinol displays anticancer efficacy in vitro and in vivo (12) (13) (14) . Thus, clioquinol may be a novel anti-cancer agent. However, pharmacological actions of clioquinol on cancer cells still remain unclear.
P21, P27, cyclin A, cyclin E and Cdk2 rabbit monoclonal antibodies were purchased from Epitomics Inc. (uSA). HRP-conjugated monoclonal mouse anti-glyceraldehyde--3-phosphate dehydrogease (GAPDH) was purchased from Kangchen Biotech (China). The secondary antibody HRP-labeled goat anti-rabbit IgG (H+L) was purchased from Novoprotein Scientific Inc. (China).
Cell line and cell culture
Human hepatoma cell line SMMC-7721 and immortal hepatocytes QSG-7701 were supplied by the Type Culture Collection of the Chinese Academy of Sciences (China). Cells were cultured at 37 °C under a humidified 5 % CO 2 atmosphere in DMEM and RPMI-1640 medium supplemented with 10 % fetal bovine serum (fBS) (GIBCO, uSA) and 1 % penicillin-streptomycin (10,000 u mL -1 penicillin and 10 mg mL -1 streptomycin (Solarbio Life Science, China).
Cell viability and apoptosis assay
Cell viability was evaluated by Cell counting kit-8 according to the manufacturer's instructions. Cells were plated in 96-well micro-well plates in 0.1 mL medium, at a density of 1 × 10 5 cells per well. The cells were incubated without clioquinol (0.1 % DMSO) or with 1, 2, 5 mmol L -1 clioquinol solution. Absorbance was measured at 450 nm with a Genios multifunction-reader (Tecan GENios Pro, Tecan Group Ltd., Switzerland). Apoptosis was examined using flow cytometry (fACScalibur, BD Bioscenices, uSA) after staining the cells with annexin V-fITC and propidium iodide (PI) (Majorbio Bio-Pharm Technology Co., China 
Cell cycle analysis
Cellular DNA content was determined by flow cytometry. After incubation with 5 mmol L -1 or 0.1 % DMSO for 48 and 72 h, cells were harvested, washed twice with ice-cold PBS, fixed with 70 % ethanol for 18 h at 4 °C. Cells were then washed twice with ice-cold PBS and re-suspended in PBS. RNA was digested with RNase A (10 μg mL 
Real-time PCR
The cells were incubated with 5 mmol L -1 clioquinol or 0.1 % DMSO for 72 h. Total RNA extraction and complementary DNA (cDNA) preparation were performed using TRNzol reagent and fastQuant RT kit (with gDNase, Tiangen, China), respectively. The real-time PCR analysis was performed in triplicate using SuperReal PreMix Plus (SYBR Green) (Tiangen, China) in a CfX96 Real-Time PCR Detection System (Bio-Rad, uSA). The reactions were as follows: activation of the Taq DNA polymerase at 95 °C for 15 min and 40 cycles of 95 °C for 10 s and 60 °C for 32 s. The primers are listed in Table I . Gapdh was selected as internal control. The relative changes in gene expression were calculated using the equation by Livak (16):
, where ΔΔC T = (C T,Target -C T,Gapdh ) Treatment -(C T,Target -C T,Gapdh ) Control C T,Target is the threshold cycle for internal reference Gapdh gene. The treatment and control mean the cells treated with and without clioquinol, respectively. Data were expressed as a fold change compared to control samples (mean ± SD of three replicates). 
Western blot
The cells were incubated with 5 mmol L -1 clioquinol or 0.1 % DMSO for 72 h. Cell lysates were obtained using standard techniques and RIPA lysis buffer (Beyotime Institute of Biotechnology, China). Protein concentration was determined by the Bradford protein assay (Bio-Rad, uSA). A quantity of 50 μg total protein per lane was separated by 12 % sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Amersham Hybond-P polyvinylidene fluoride (PVDf) membranes (GE Healthcare). Membranes were blocked with 5 % milk powder in 0.05 % Tween-Tris buffer saline (TBS), incubated with specific primary antibodies and then with the appropriate horseradish peroxidase-conjugated secondary antibodies (Sinbio, China). GAPDH was used as an internal standard. Detection of the target proteins on the membranes was performed using the ECL western blotting detection reagents (GE Healthcare, uK). Signal density was detected using the Mf-ChemiBIS family including gel capture software (DNR Bio-Image system, Ltd., Israel) and quantitatively analyzed by densitometry using the Image J software.
Statistical analysis
The experiments were repeated three times. The data are presented as the mean ± SD (for each group). Statistical analysis was performed using Student's t-test (paired). Values of p < 0.05 were considered to be statistically significant. RESuLTS 
AND DISCuSSION

Clioquinol causes SMMC-7721 cell death
using the wST-8 based colorimetric assay cell counting kit 8, the effects of clioquinol on cell viability were measured. As shown in Fig. 1a , clioquinol induced a time-and concentration-dependent decrease in the viability of SMMC-7721 cells. After 72 hours of treatment, the half maximal inhibitory concentration (IC 50 ) of clioquinol was 1.0 mmol L -1 . It is noteworthy that clioquinol did not induce significant decrease in the viability of normal human liver cells QSG-7701 (fig. 1b) . Obviously, the cell growth inhibitory effect of clioquinol on the human hepatoma SMMC-7721cells was stronger than that on the normal liver QSG-7701cells. In addition, the highest concentration of clioquinol (5 mmol L -1 ) in our study did not exhibit significant cytotoxicity in QSG-7701 cells. The results further confirmed that clioquinol has low side effects (8) (9) (10) (11) . 
Clioquinol does not induce cell apoptosis and autophagy
Cell cycle arrest is induced by clioquinol
To examine whether clioquinol-induced growth inhibition was associated with cell cycle regulation, the cell cycle distribution was analyzed by flow cytometry. S phase were 35.2 % and 36.6 % in control SMMC-7721 cells. However, after 48 and 72 h of incubation with 5 mmol L -1 clioquinol, the S population was noticeably enhanced by 44.8 and 58.2 %, respectively (p < 0.05) (Fig. 3) . fig. 3 . Clioquinol inhibits cell cycle progression and causes S-phase arrest in SMMC-7721 cells.
Changes of cell cycle related genes mRNA and proteins expression
In order to determine whether clioquinol was able to regulate cell cycle related gene expression, a real-time PCR experiment was performed in the cell extracts prepared from SMMC-7721 cells. The results showed that clioquinol reduced the levels of cyclin A2, cyclin D1, cyclin E1 and Cdk2 (p < 0.05), and increased the levels of p21 and p27 72 h after treatment (p < 0.01) (fig. 4) . Next, western blot with specific antibodies was done to detect the changes of the related protein expression levels. we observed a reduction of cyclin A2, cyclin D1, cyclin E1 and Cdk2 and an increase of p21 and p27 after the treatment with clioquinol for 72 h ( fig. 5) . Therefore, clioquinol regulates mRNA and subsequent protein levels of certain cell cycle-related genes to induce the S-phase cell cycle arrest in SMMC-7721 cells.
Clioquinol has been shown to have anticancer activity in several experimental model systems via several different mechanisms of action. for instance, it generates free zinc in lysosomes as a zinc ionophore (17) , inhibits Nf-kappa B activity (12, 17, 18) , or proteasome activity (8, 9, 19) , induces the cytoplasmic clearance of X-linked inhibitor of apoptosis protein (20) , or induces DNA double-strand break and subsequent activation of ATM/p53 signaling (21) . The present study firstly demonstrated that clioquinol induced cell-cycle arrest in the S phase in SMMC-7721 hepatoma cells. furthermore, according to the current data, the S phase arrest in clioquinol treated SMMC-7721 cells was accompanied by the alteration of various cell cycle-related proteins. SMMC-7721 cells treated with clioquinol showed down-regulation of cyclin A2, cyclin D1, cyclin E1 and Cdk2, and up-regulation of p21 and p27. A previous study has reported that the S phase cell-cycle arrest occurs with the loss of Cdk2 activity due to up-regulation of p21 and reduced formation of active complex cyclin E/Cdk2 kinase (22) . Yeo et al. (23) suggested that an intra-S-phase checkpoint occurs via phosphorylation of Chk1/2, which leads to degradation of cdc25A and deactivation of cyclin E/A-Cdk2 complex. In this study, up-regulation of p21, p27 and down-regu- lation of cyclin E1, cyclin A2 and Cdk2 are considered to be involved in the S-phase arrest induced by clioquinol in SMMC-7721 cells. In addition, clioquinol regulates the mRNA levels of these cell cycle-related genes and results in subsequent protein levels to induce the S-phase cell cycle arrest in SMMC-7721 cells. However, the cell cycle regulation by clioquinol needs to be elucidated further.
CONCLuSIONS
Our preliminary findings demonstrate for the first time that clioquinol exerts its cell death effects via S-phase cell-cycle arrest in SMMC-7721 hepatoma cells. Additionally, the growth inhibitory effect after exposure to clioquinol is not caused by apoptosis and/or autophagy in SMMC-7721 cells. Although clioquinol exhibits different modes of action in different types of cancer cells, here it suppresses cell cycle progression in the S-phase in SMMC-7721 cells via the p21, p27-cyclin E,A/Cdk2 pathway. Our results strongly suggest that clioquinol should be additionally investigated as a potential novel chemotherapeutic agent for the treatment of some malignant human cancers.
